RISK FACTORS FOR NONCOMPLIANCE WITH ANTIPSYCHOTIC MEDICATION IN LONG-TERM TREATED CHRONIC SCHIZOPHRENIA PATIENTS

被引:0
|
作者
Krzystanek, Marek [1 ]
Krysta, Krzysztof [1 ]
Janas-Kozik, Malgorzata [2 ,3 ]
Martyniak, Ewa [1 ]
Rybakowski, Janusz [4 ]
机构
[1] Med Univ Silesia, Dept Rehabil Psychiat, Ziolowa 45-47, PL-40635 Katowice, Poland
[2] Med Univ Silesia, Dept Psychiat & Psychotherapy, Dev Age Clin Ward, Katowice, Poland
[3] John Paul II Pediat Ctr, Sosnowiec, Poland
[4] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland
关键词
schizophrenia; compliance; drug attitude; antipsychotics; long-term treatment; DRUG ATTITUDE; INSIGHT; OUTPATIENTS; ADHERENCE; REMISSION; CRITERIA;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: The attitudes of schizophrenic patients toward medications directly impact the treatment compliance. Although noncompliance represents a serious concern in long-term schizophrenia treatment, a detailed information on the factors that impair compliance is still limited. The present study aims to assess the factors related to noncompliance with antipsychotics agents, in longterm treated chronic paranoid schizophrenia patients. Subjects and methods: Two groups of such patients (total number n=162) were analyzed and compared: 1). patients with symptomatic remission on haloperidol (n=32), clozapine (n=40) or olanzapine (n=45), and 2). drug resistant patients (n=45). The mean duration of the disease was 19.3 years. Results: Altogether, in our patient sample, a better drug attitude was found in the olanzapine and clozapine groups. Our findings have also revealed that worse attitude toward antipsychotics correlated with an earlier onset of schizophrenia, younger patient age, shorter duration of the disease, higher burden of symptoms, treatment with a typical antipsychotics, and higher severity of akathisia. Conclusion: Our results suggest that detecting factors that influence the patient's attitude toward medications might be helpful for designing targeted educational strategies in chronic schizophrenia patients (particularly those with the high risk of noncompliance), and further trials are warranted to explore this topic.
引用
收藏
页码:S543 / S548
页数:6
相关论文
共 50 条
  • [21] Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
    De Hert, MA
    van Winkel, R
    Van Eyck, D
    Hanssens, L
    Wampers, M
    Scheen, A
    Peuskens, J
    SCHIZOPHRENIA RESEARCH, 2006, 83 (01) : 87 - 93
  • [22] Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
    De Hert, M.
    van Winkel, R.
    Van Eyck, D.
    Hanssens, L.
    Wampers, M.
    Scheen, A.
    Peuskens, J.
    DRUG SAFETY, 2006, 29 (10) : 980 - 980
  • [23] Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia: observational study
    Yu, Wenjuan
    Huang, Jingjing
    He, Sidi
    Zhang, Lei
    Shen, Yifeng
    Li, Huafang
    GENERAL PSYCHIATRY, 2021, 34 (01)
  • [24] Safety and related factors of treatment with long-term atypical antipsychotic in Chinese patients with schizophrenia:observational study
    Wenjuan Yu
    Jingjing Huang
    Sidi He
    Lei Zhang
    Yifeng Shen
    Huafang Li
    上海精神医学, 2021, (01) : 37 - 43
  • [25] The long-term effects of placebo in patients with chronic schizophrenia
    Wyatt, RJ
    Henter, ID
    Bartko, JJ
    BIOLOGICAL PSYCHIATRY, 1999, 46 (08) : 1092 - 1105
  • [26] Clozapine as a short-term antipsychotic medication in patients with schizophrenia
    Chan, YC
    SCHIZOPHRENIA RESEARCH, 2006, 81 (01) : 115 - 117
  • [27] A LONG-TERM OUTCOME STUDY OF TARDIVE-DYSKINESIA IN PATIENTS ON ANTIPSYCHOTIC MEDICATION
    KOSHINO, Y
    WADA, Y
    ISAKI, K
    KURATA, K
    CLINICAL NEUROPHARMACOLOGY, 1991, 14 (06) : 537 - 546
  • [28] LONG-TERM RISK-FACTORS OF ANTICANCER MEDICATION FOR CHILDREN
    VASSAL, G
    PEIN, F
    ARCHIVES DE PEDIATRIE, 1995, 2 : S104 - S105
  • [29] LONG-TERM HEALTH OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH THE LONG-ACTING INJECTABLE ANTIPSYCHOTIC ARIPIPRAZOLE LAUROXIL FOR 1 YEAR
    Gasper, S. M.
    Dingman, S.
    Wang, M.
    Roy, B. D.
    VALUE IN HEALTH, 2022, 25 (07) : S314 - S315
  • [30] Comparison of the metabolic syndrome risk factors in antipsychotic naive and chronic schizophrenia patients
    Robabeh, Soleimani
    Somayeh, Shokrgozar
    Masoomeh, Shekarriz-Fumani
    Melikad, Jalali Seyede
    ARCHIVES OF PSYCHIATRY AND PSYCHOTHERAPY, 2021, 23 (03): : 44 - 54